Drug Profile
Research programme: CD26 antigen inhibitors - Kainos Medicine
Alternative Names: Dipeptidyl peptidase IV inhibitors - Kainos Medicines; DPP-IV inhibitor - Kainos; KM-223Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Korea Research Institute of Chemical Technology
- Developer Kainos Medicines
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in South Korea